40 mg CBL-514 + 60 mg CBL-514 + 80 mg CBL-514
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cellulite
Conditions
Cellulite
Trial Timeline
Jan 9, 2023 → May 3, 2023
NCT ID
NCT05632926About 40 mg CBL-514 + 60 mg CBL-514 + 80 mg CBL-514
40 mg CBL-514 + 60 mg CBL-514 + 80 mg CBL-514 is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Cellulite. The current trial status is completed. This product is registered under clinical trial identifier NCT05632926. Target conditions include Cellulite.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05632926 | Phase 2 | Completed |
Competing Products
1 competing product in Cellulite
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CBL-514 injection | Caliway Biopharmaceuticals | Phase 2 | 51 |